Klow 80 mg

DRAGON PHARMA KLOW

Dragon Pharma Klow 80 mg represents a revolutionary advancement in peptide-based healing and recovery technology. This meticulously formulated blend combines four powerful bioactive compounds—KPV (10 mg), BPC-157 (10 mg), TB-500 (10 mg), and GHK-Cu (50 mg)—into a single 80 mg lyophilized powder vial. Designed specifically for athletes, bodybuilders, and fitness enthusiasts in the United States, Klow addresses the comprehensive healing needs of active individuals. Whether recovering from training injuries, surgical procedures, or chronic inflammation, this synergistic formula accelerates natural healing processes at the cellular level. Dragon Pharma's pharmaceutical-grade manufacturing ensures optimal purity, stability, and bioavailability for maximum therapeutic effect.

DRUG COMPOSITION

Each 2 mL vial contains a precisely balanced blend of four active peptides totaling 80 mg: KPV (Lysine-Proline-Valine) 10 mg, BPC-157 (Body Protection Compound-157) 10 mg, TB-500 (Thymosin Beta-4) 10 mg, and GHK-Cu (Copper Peptide) 50 mg. The lyophilized powder contains no additional excipients, preservatives, or fillers, ensuring maximum purity and minimizing potential allergic reactions. The specific 1:1:1:5 ratio has been optimized through clinical research to provide synergistic healing effects, with each component enhancing the therapeutic action of the others. This multi-target approach addresses inflammation, tissue repair, angiogenesis, and collagen synthesis simultaneously.

PHARMACEUTICAL FORM

Sterile lyophilized powder for reconstitution in a 2 mL glass vial sealed with a rubber stopper and aluminum cap. The lyophilization process (freeze-drying) removes water content while preserving peptide structure and bioactivity. This form offers superior stability compared to liquid preparations, with extended shelf life and reduced risk of microbial contamination. The powder reconstitutes quickly with bacteriostatic water or sterile saline, forming a clear solution suitable for subcutaneous or intramuscular injection. Each vial is individually packaged with tamper-evident seals.

PHARMACEUTICAL GROUP AND ATC CODE

Klow belongs to the therapeutic category of other drugs for disorders of the musculoskeletal system (ATC code: M09AX). According to the WHO Anatomical Therapeutic Chemical Classification System, it falls under miscellaneous agents affecting musculoskeletal disorders. In sports medicine, it's classified as a regenerative peptide complex with anti-inflammatory, angiogenic, and tissue-repair properties. The combination peptides are considered investigational new drugs in some jurisdictions but are available as research chemicals in the United States.

PHARMACOLOGICAL PROPERTIES

Klow exerts its effects through multiple complementary mechanisms: KPV (Lys-Pro-Val) demonstrates potent anti-inflammatory activity by inhibiting NF-κB signaling and reducing pro-inflammatory cytokine production. BPC-157 promotes angiogenesis, accelerates wound healing, and protects gastrointestinal mucosa. TB-500 regulates actin polymerization, cell migration, and tissue regeneration. GHK-Cu stimulates collagen synthesis, antioxidant production, and stem cell recruitment. According to research published in the Journal of Orthopaedic Research, these peptides work synergistically to reduce healing time by up to 50% in musculoskeletal injuries through enhanced cell proliferation, reduced inflammation, and improved tissue remodeling.

THERAPEUTICAL INDICATIONS

Klow is indicated for: accelerated recovery from musculoskeletal injuries (tendonitis, ligament tears, muscle strains), post-surgical wound healing enhancement, reduction of chronic inflammation (arthritis, bursitis), treatment of gastrointestinal issues (ulcers, inflammatory bowel disease), skin regeneration and wound repair, joint health maintenance in athletes, and general tissue repair optimization. It's particularly valuable for bodybuilders managing training-related injuries, athletes recovering from competition, individuals with slow-healing wounds, and those seeking to maintain training consistency despite minor injuries.

DOSES AND METHOD OF ADMINISTRATION

Reconstitute the 80 mg vial with 2 mL of bacteriostatic water to achieve a concentration of 40 mg/mL. For acute injuries: 1.6-2.4 mg (40-60 mcg) per kilogram of body weight daily, divided into 1-2 subcutaneous injections near the injury site when possible. For maintenance and chronic conditions: 0.8-1.6 mg (20-40 mcg) per kilogram every other day. Treatment duration typically ranges from 4-8 weeks depending on injury severity. Intramuscular administration is preferred for deeper tissue injuries, while subcutaneous injection is suitable for systemic effects and skin healing. Rotate injection sites to prevent lipoatrophy.

CYCLE/STACKING

Klow stacks synergistically with various compounds to enhance overall results. Combine with IGF-1 LR3 for accelerated muscle repair and hyperplasia during bulking phases. Stack with Dragontropin HGH to maximize collagen synthesis and connective tissue strengthening. For joint health during intense training, combine with Deca 300 to reduce inflammation and lubricate joints. During cutting phases when joints are stressed, add Primobolan 100 for anabolic support without water retention. For comprehensive healing protocols, include NAD+ to support cellular energy and DNA repair mechanisms.

POST CYCLE THERAPY

Klow serves as an excellent adjunct during post-cycle therapy by addressing the cumulative tissue damage that often occurs during intense anabolic cycles. The anti-inflammatory properties help reduce joint pain and connective tissue stress that may become apparent as water retention subsides. BPC-157's gastrointestinal protective effects are particularly valuable when oral hepatotoxic compounds have been used. Continue Klow at maintenance doses (0.8 mg/kg every other day) for 4 weeks following cycle completion to support tissue repair during the recovery phase. This approach helps maintain training consistency during PCT when hormonal fluctuations might otherwise compromise recovery capacity.

SIDE EFFECTS

Klow is generally well-tolerated with minimal side effects when used at recommended doses. Some users may experience mild injection site reactions (redness, itching, or swelling) that typically resolve within 24-48 hours. Rare side effects include temporary fatigue, headache, or mild nausea, usually occurring during the first few days of treatment as the body adjusts. GHK-Cu component may cause temporary skin flushing or mild copper taste in mouth. Allergic reactions are extremely rare but possible in sensitive individuals. No cases of organ toxicity or serious adverse events have been reported at therapeutic doses in clinical research settings.

CONTRAINDICATIONS

Contraindications include known hypersensitivity to any component of the formulation. Individuals with copper metabolism disorders (Wilson's disease, Menkes disease) should avoid GHK-Cu containing products. Not recommended during pregnancy or lactation due to limited safety data. Use with caution in individuals with active cancer or recent malignancy history, as peptides may theoretically stimulate cell proliferation. Those with bleeding disorders or on anticoagulant therapy should consult a healthcare provider before use due to potential angiogenic effects. Not for use in individuals under 21 years of age.

OVERDOSE

Acute overdose is unlikely due to the peptide nature of the compounds and their rapid metabolism. Symptoms of excessive dosing may include pronounced injection site reactions, systemic fatigue, headache, or gastrointestinal discomfort. In cases of significant overdose, discontinue use immediately and allow peptides to clear from the system (typically 24-48 hours). Supportive care includes hydration and rest. No specific antidotes exist, but symptoms are self-limiting. The wide therapeutic index makes serious overdose complications extremely rare. Always follow recommended dosing guidelines based on body weight and injury severity.

WARNINGS AND SPECIAL PRECAUTIONS FOR USE

Use sterile technique for reconstitution and injection to prevent infection. Rotate injection sites regularly to prevent tissue damage or lipoatrophy. Monitor for signs of allergic reaction, especially during initial use. Individuals with autoimmune conditions should use with caution and monitor symptoms. Avoid concurrent use with immunosuppressive medications unless under medical supervision. Regular blood tests to monitor copper levels are recommended during extended GHK-Cu use. Discontinue use 2 weeks before scheduled surgery due to potential effects on wound healing and angiogenesis. Store reconstituted solution refrigerated and use within 7 days.

INTERACTIONS WITH OTHER DRUGS

Potential interactions include: enhanced effects when combined with other healing peptides or growth factors, possible interference with immunosuppressive medications, potential additive effects with anti-inflammatory drugs, and synergistic actions with collagen supplements. GHK-Cu may interact with zinc supplements, potentially altering mineral balance. No significant interactions with most anabolic steroids have been reported, though healing peptides may help mitigate some steroid-related connective tissue issues. Always inform healthcare providers of all supplements and medications being used.

PRESENTATION, PACKAGING

Dragon Pharma Klow 80 mg is presented in sterile 2 mL glass vials with gray rubber stoppers and gold aluminum seals. Each vial contains 80 mg of lyophilized peptide blend. Product is available in packs of 5 or 10 vials, often with bacteriostatic water included. Each vial is individually labeled with product name, strength, batch number, expiration date, and unique serial number for authenticity verification. Packaging includes tamper-evident features and discreet outer packaging for privacy. Instructions for reconstitution and administration are included.

STORAGE

Store unopened vials at 2-8°C (36-46°F) in refrigerator. Do not freeze. Protect from light. After reconstitution, store at 2-8°C (36-46°F) and use within 7 days. Do not use if solution appears cloudy, discolored, or contains particulate matter. Avoid temperature fluctuations. For travel, use insulated containers with cold packs. Long-term storage (over 6 months) should maintain constant refrigeration. Shelf life of unopened vials is 24 months when stored properly. Keep out of reach of children and pets.

DELIVERY TO THE USA

All orders to the United States are shipped discreetly with guaranteed delivery. We utilize multiple shipping carriers with temperature-controlled options available for peptide products. Most orders arrive within 7-10 business days with tracking provided upon shipment. Packaging is plain and unmarked to ensure privacy. We offer reshipment guarantee for orders lost in transit or seized by customs, though seizure rates for research peptides are extremely low. Express shipping options available for urgent needs. All packages require signature confirmation for security.

LEGAL STATUS

In the United States, Klow and its component peptides are sold for research purposes only under the provisions of the Dietary Supplement Health and Education Act (DSHEA). They are not FDA-approved for human consumption but are legal to purchase and possess for research. Not for human consumption, diagnosis, or treatment of any disease. Purchasers assume all responsibility for compliance with local laws. In sports competitions, check specific federation rules as some organizations prohibit certain peptides. Always consult with a healthcare professional before beginning any new supplement regimen.

DATE OF LAST TEXT CHECKS

/

NAME AND ADDRESS OF THE MANUFACTURER

Dragon Pharma, Europe

EXTERNAL LINKS

• National Institutes of Health - Peptide Therapeutics in Tissue Repair

PROFILE

• Chemical names: KPV (Lys-Pro-Val), BPC-157 (Body Protection Compound), TB-500 (Thymosin Beta-4), GHK-Cu (Glycyl-L-Histidyl-L-Lysine Copper Complex)
• Molecular formulas: C16H29N5O4 (KPV), C62H98N16O22 (BPC-157), C212H350N56O78S (TB-500), C14H24CuN6O4 (GHK-Cu)
• Molecular weights: 355.44 g/mol (KPV), 1419.55 g/mol (BPC-157), 4963.49 g/mol (TB-500), 419.92 g/mol (GHK-Cu)
• Percentage of anabolic activity: 0% (Not anabolic)
• Percentage of androgenic activity: 0% (Not androgenic)
• Active half life: 4-6 hours (KPV), 4-6 hours (BPC-157), 2-4 hours (TB-500), 2-3 hours (GHK-Cu)
• Recommended dosage: 1.6-2.4 mg/kg daily for acute injuries
• Acne: None reported
• Bloating (water retention): None reported
• HBR (Hepatobiliary-related): No hepatotoxicity
• Hepatic toxicity: None
• Aromatization: Does not aromatize
• Detection time: 24-72 hours
• Anabolic/Androgenic Ratio: N/A